内容紹介
Adjuvant Hormonal Treatment for Estrogen Receptor-Positive Breast Cancer―A Questionnaire Survey Conducted by Japanese Breast Cancer Society-Authorized Facilities in Hokkaido
Summary
According to the Japanese Breast Cancer Society national breast cancer registration, 71.8% of breast cancer cases reported in 2004 and 79.8% of cases reported in 2010 were estrogen receptor(ER)positive. The frequency of ER-positive breast cancer is increasing annually in Japan. Many clinical trials have proven that adjuvant hormonal treatment affects both progression-free survival and overall survival in ER-positive breast cancer cases. However, some clinical questions remain, including those regarding the definition of preoperative hormonal treatment, appropriate dosage period, and therapeutic drug choice. In January 2013, we conducted a questionnaire survey of 53 medical doctors engaged in breast cancer treatment at 15 Japanese Breast Cancer Society-authorized facilities in Hokkaido. This survey included 6 clinical questions about preoperative hormonal treatment, 5 clinical questions about postoperative hormonal treatment for premenopausal breast cancer, and 4 clinical questions about postoperative hormonal treatment for postmenopausal breast cancer. We obtained replies from 35 medical doctors at 27 facilities. The response rate was 66%. We accumulated and analyzed these data. The discussion of questionnaire results in the medical administration field facilitates the sharing of information regarding differences in the approaches of different facilities to breast cancer patients. As a result, standardization of the breast cancer medical treatment system in this area has been accomplished.」
要旨
エストロゲン受容体(ER)陽性乳がん症例に関する周術期治療方針については,医師により方針が統一されていない事項が存在する。方法: 2013年1月,北海道地区の日本乳癌学会認定15施設および関連30施設の乳がん治療に携わる医師53名に,15問からなるアンケート調査を依頼した。初期治療(術前内分泌療法),閉経前術後内分泌療法,閉経後術後内分泌療法に関して質問した。結果: 27施設35名の乳がん治療に携わる医師から回答を得て,それを集計した(回収率66%)。術前内分泌療法を実施している施設は71%あった。骨粗鬆症の症例では,閉経後術後治療としてタモキシフェン投与が考慮されていた。アンケートで施設間の治療指向の違いを確認できた。結論: アンケート調査を通じた地域施設間の情報共有は,医療の均てん化に貢献する。
目次
Summary
According to the Japanese Breast Cancer Society national breast cancer registration, 71.8% of breast cancer cases reported in 2004 and 79.8% of cases reported in 2010 were estrogen receptor(ER)positive. The frequency of ER-positive breast cancer is increasing annually in Japan. Many clinical trials have proven that adjuvant hormonal treatment affects both progression-free survival and overall survival in ER-positive breast cancer cases. However, some clinical questions remain, including those regarding the definition of preoperative hormonal treatment, appropriate dosage period, and therapeutic drug choice. In January 2013, we conducted a questionnaire survey of 53 medical doctors engaged in breast cancer treatment at 15 Japanese Breast Cancer Society-authorized facilities in Hokkaido. This survey included 6 clinical questions about preoperative hormonal treatment, 5 clinical questions about postoperative hormonal treatment for premenopausal breast cancer, and 4 clinical questions about postoperative hormonal treatment for postmenopausal breast cancer. We obtained replies from 35 medical doctors at 27 facilities. The response rate was 66%. We accumulated and analyzed these data. The discussion of questionnaire results in the medical administration field facilitates the sharing of information regarding differences in the approaches of different facilities to breast cancer patients. As a result, standardization of the breast cancer medical treatment system in this area has been accomplished.」
要旨
エストロゲン受容体(ER)陽性乳がん症例に関する周術期治療方針については,医師により方針が統一されていない事項が存在する。方法: 2013年1月,北海道地区の日本乳癌学会認定15施設および関連30施設の乳がん治療に携わる医師53名に,15問からなるアンケート調査を依頼した。初期治療(術前内分泌療法),閉経前術後内分泌療法,閉経後術後内分泌療法に関して質問した。結果: 27施設35名の乳がん治療に携わる医師から回答を得て,それを集計した(回収率66%)。術前内分泌療法を実施している施設は71%あった。骨粗鬆症の症例では,閉経後術後治療としてタモキシフェン投与が考慮されていた。アンケートで施設間の治療指向の違いを確認できた。結論: アンケート調査を通じた地域施設間の情報共有は,医療の均てん化に貢献する。